| Methods |
Allocation concealment: computer generated sealed consecutively numbered envelopes
Blinding of study: no
Support: Pfizer |
| Participants |
164 participants total
Excluded: 22
Other cancer, empirically |
| Interventions |
Fluconazole: 400 mg/d iv
Amphotericin B: 25‐50 mg/d iv |
| Outcomes |
Death
Infections
Number of dropouts because of adverse effects |
| Notes |
Follow‐up period (days): NA
Days on fluconazole: 11
Days on amphotericin B: 11
Support: Pfizer |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Low risk |
A ‐ Adequate |
| Blinding (performance bias and detection bias)
All outcomes |
High risk |
|
